Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | WDR5 | P61964 | 3/20 | 0.45 |
| ▸ | BRS3 | P32247 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.45 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.45 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.45 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.45 |
| ▸ | ATP4A | P20648 | 2/20 | 0.45 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.45 |
| ▸ | ATP4B | P51164 | 2/20 | 0.45 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.45 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.45 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772475 | 1.00 | KMT2A (0.45) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL3046965 | 0.90 | KMT2A (0.45) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL6770854 | 0.90 | KMT2A (0.45) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL7846721 | 0.89 | KMT2A (0.44) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL12021142 | 0.87 | BRS3 (0.46) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL9279388 | 0.87 | KMT2A (0.40) | KMT2AWDR5BRS3ATP4AATP4B | |
| SCHEMBL9269042 | 0.86 | ALDH1A1 (0.42) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL6771448 | 0.86 | KMT2A (0.43) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL6773081 | 0.86 | KMT2A (0.43) | KMT2AWDR5BRS3CYP2C9ATP1A1 | |
| SCHEMBL9445988 | 0.85 | KMT2A (0.41) | KMT2AWDR5BRS3CYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673819-B2 | NITRIC OXIDE RELEASING COMPOUND | ASTRAZENECA AB (SE) | 2004-01-06 | — | — | US | disclosed |
| EP-1370551-A2 | NEW COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| US-20020111370-A1 | Compounds useful as antibacterial agents | ASTRAZENECA AB (SE) | 2002-08-15 | — | — | US | disclosed |
| WO-2002000166-A2 | NEW COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| US-5215974-A | Antisecretory agents for gastrointestinal disorders; water solubility, chemical stability | AKTIEBOLAGET HASSLE (SE) | 1993-06-01 | — | — | US | disclosed |
| EP-0279149-B1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1992-12-30 | — | — | EP | disclosed |
| EP-0332647-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1989-09-20 | — | — | EP | disclosed |
| EP-0279149-A2 | Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same | Aktiebolaget Hässle (SE) | 1988-08-24 | — | — | EP | disclosed |
| WO-1988003921-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1988-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111370-A1 | Compounds useful as antibacterial agents | NOS1, NOS2, PTGS1 | KMT2A 4205/4885WDR5 3682/4885BRS3 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.